Azasetron

Azasetron
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code none
Pharmacokinetic data
Bioavailability 90%
Excretion 60-70%
Identifiers
CAS Number 123039-99-6
PubChem (CID) 2264
IUPHAR/BPS 2285
ChemSpider 2177 YesY
UNII 77HC7URR9Z YesY
KEGG D07481 YesY
ChEMBL CHEMBL1598608
Chemical and physical data
Formula C17H20ClN3O3
Molar mass 349.81 g/mol
3D model (Jmol) Interactive image
  (verify)

Azasetron is an antiemetic which acts as a 5-HT3 receptor antagonist , pKi = 9.27 [1] It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone® I.V. Injection 10 mg" and "Serotone® Tablets 10 mg".[2] Pharmacokinetics data from S. Tsukagoshi.[3]

References

  1. "Azasetron". http://drugcentral.org/. UNM School of Medicine. 2016-07-31. Retrieved 2016-11-11. External link in |website= (help)
  2. "Torii Pharmaceutical to Solely Market Antiemetic Drugs". Torii Pharmaceutical Co Ltd. 2009-01-13. Retrieved 2016-11-11.
  3. Tsukagoshi, S. (1999-06-01). "[Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]". Gan to Kagaku Ryoho. Cancer & Chemotherapy. 26 (7): 1001–1008. ISSN 0385-0684. PMID 10396331.


This article is issued from Wikipedia - version of the 11/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.